ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2021 and some content may be unavailable. To unlock all content for 2021, please visit the archives.

Abstract: PO0017

AKI Associated with COVID-19: Differences Between Previously Healthy Kidney Individuals and CKD Patients

Session Information

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Musso, Carlos Guido, Instituto Universitario del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
  • Aroca Martinez, Gustavo, universidad simon bolivar, Barranquilla, Colombia
  • Avendaño-Echavez, Lil Geraldine, universidad simon bolivar, Barranquilla, Colombia
  • Velez-Verbel, Maria De los angeles, Clinica de la Costa Ltda, Barranquilla, Atlántico, Colombia
  • Chartouni Narvaez, Stefani, universidad simon bolivar, Barranquilla, Colombia
  • Hernandez-Agudelo, Sandra Yolima, Clinica de la Costa Ltda, Barranquilla, Atlántico, Colombia
  • Hinojosa, Mauricio, Clinica de la Costa Ltda, Barranquilla, Atlántico, Colombia
  • Espitaleta, Zilac, universidad simon bolivar, Barranquilla, Colombia
  • Cadena-Bonfanti, Andres, universidad simon bolivar, Barranquilla, Colombia
Background

Renal injury associated to COVID-19 has an incidence of 3-9%, which ranged from urinary abnormalities up to acute kidney injury (AKI-COVID19), which is mainly observed in critical care patients. The main risk factors for AKI-COVID19 appearance are: oncologic disease, sepsis, heart failure. However, it has not described if there are differences between AKI-COVID19 in patients with previously healthy kidney (AKI-NRF) and those with chronic kidney disease (AKI-CKD), thus we decided to explore it in patients who were assisted during the first pandemic wave (2020) in Clinica de la Costa, Barranquilla, Colombia

Methods

572 patients with confirmed diagnosis of COVID-19 (PCR) were evaluated. Out of them 188 developed AKI and their epidemiological data, serum parameters, and functional status were recorded. Statistical analysis and comparison between AKI-NRF and AKI-CKD patients were performed

Results

From 720 individuals evaluated at the emergency room for suspicion of COVID-19, 572 of them were admitted with confirmed SARS-CoV-2 infection. Most of them were male (59%), median age 55 years, with hypertension (36%), obesity (23%), diabetes (18%), heart disease (5%), and COPD (9%). Almost all patients were robust (97%). 188 COVID-19 patients developed AKI (33%), although 149 (26%) presented a previous normal renal function (AKI-NRF), while 39 (7%) had CKD (AKI-CKD). Most of CKD patients (91%) developed AKI. There was a predominance of male gender, old age (≥ 60 years), frailty status (CFS ≥ 4), diabetes mellitus, obesity, COPD in AKI group (AKI-NRF and AKI-CKD subgroups) respect to NO AKI group (n: 380). The prevalence of hypertension and cardiac disease was significantly higher in AKI-CKD respect to AKI-NRF, and even higher respect to NO AKI. However, there was a tendency of higher mortality rate in AKI-NRF (69%) compared to AKI-CKD (56%). Even though, this trend did not reach statistical significance (p=0.09), mortality rate in AKI compared to NO AKI (16%) (p=<0.0001) did. D-dimer was slightly higher in AKI-NRF compared to AKI-CKD (p=0.06)

Conclusion

There was a trend to higher mortality rate and D-dimer levels in AKI-NRF individual compared to AKI-CKD patients